{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:32:15Z","timestamp":1791304335455,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s40263-023-01000-z","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T11:24:43Z","timestamp":1680607483000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use"],"prefix":"10.1007","volume":"37","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"2","key":"1000_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/CND.0000000000000377","volume":"23","author":"SMD Beladakere Ramaswamy","year":"2021","unstructured":"Beladakere Ramaswamy SMD, Singh S, Hooshmand S, et al. Current and upcoming treatment modalities in myasthenia gravis. J Clin Neuromuscul Dis. 2021;23(2):75\u201399.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"1000_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"11","key":"1000_CR3","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, et al. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"1","key":"1000_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2020.102712","volume":"20","author":"AM Lascano","year":"2021","unstructured":"Lascano AM, Lalive PH. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun Rev. 2021;20(1):1\u20136.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"1000_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar MK, Abumurad S, Soliven B, et al. Current treatment of myasthenia gravis. J Clin Med. 2022;11(6):1\u201323.","journal-title":"J Clin Med"},{"issue":"5","key":"1000_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1002\/mus.26919","volume":"62","author":"AA Habib","year":"2020","unstructured":"Habib AA, Ahmadi Jazi G, Mozaffar T. Update on immune-mediated therapies for myasthenia gravis. Muscle Nerve. 2020;62(5):579\u201392.","journal-title":"Muscle Nerve"},{"issue":"3","key":"1000_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R. Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics. 2022;19(3):1\u201314.","journal-title":"Neurotherapeutics"},{"key":"1000_CR8","unstructured":"Argenx. Vyvgart (efgartigimod alfa-fcab) injection, for intravenous use: US prescribing information; 2022. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8aefc8e3-26d6-4ff6-aab9-a7542927e084. Accessed 7 Feb 2023."},{"key":"1000_CR9","unstructured":"European Medicine Agency. Vyvgart (efgartigimod alfa): EU summary of product characteristics; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vyvgart-epar-product-information_en.pdf. Accessed 7 Feb 2023."},{"key":"1000_CR10","unstructured":"Pharmaceuticals and Medical Devices Agency. Vyvgart\u00ae for intravenous infusion 400 mg: Japanese prescribing information; 2022. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6399430. Accessed 11 Jan 2023."},{"key":"1000_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2019.03.001","volume":"317","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Plomp JJ, van Es IE, et al. Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis. Exp Neurol. 2019;317:133\u201343.","journal-title":"Exp Neurol"},{"issue":"10","key":"1000_CR12","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Investig. 2018;128(10):4372\u201386.","journal-title":"J Clin Investig"},{"issue":"7","key":"1000_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526\u201336.","journal-title":"Lancet Neurol"},{"issue":"23","key":"1000_CR14","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373.","journal-title":"Neurology"},{"key":"1000_CR15","unstructured":"Pulley M, Pasnoor M, Gelinas D, et al. The effect of obesity in efficacy and safety in the ADAPT trial of efgartigimod for generalized myasthenia gravis [abstract no. 194]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022."},{"issue":"Suppl 27","key":"1000_CR16","first-page":"S28","volume":"90","author":"V Bril","year":"2021","unstructured":"Bril V, Murai H, Vu T, et al. Analysis of efgartigimod efficacy across patient populations and myasthenia gravis specific scales: results of the phase 3 ADAPT study [abstract no. 304]. Ann Neurol. 2021;90(Suppl 27):S28.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"1000_CR17","first-page":"S90","volume":"64","author":"C Karam","year":"2021","unstructured":"Karam C, Vu T, Bril V, et al. Efgartigimod treatment of patients with generalized myasthenia gravis demonstrates consistent improvements across all muscle subgroups and regardless of background immunosuppressive therapy [abstract]. Muscle Nerve. 2021;64(Suppl 1):S90\u20131.","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"1000_CR18","first-page":"S5","volume":"64","author":"J Howard","year":"2021","unstructured":"Howard J, Bril V, Vu T, et al. Examination of the efficacy, safety, and tolerability of efgartigimod in acetylcholine receptor autoantibody seronegative patients with generalized myasthenia gravis: subgroup analysis of phase 3 [abstract no. 6]. Muscle Nerve. 2021;64(Suppl 1):S5.","journal-title":"Muscle Nerve"},{"issue":"9","key":"1000_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-abn2.2","volume":"93","author":"S Jacob","year":"2022","unstructured":"Jacob S, Howard J, Bril V, et al. Long-term assessment of efgartigimod in patients with generalised myasthenia gravis: ADAPT+ study interim results [abstract]. J Neurol Neurosurg Psychiatry. 2022;93(9): e2.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1000_CR20","doi-asserted-by":"crossref","unstructured":"Howard J, Bril V, Vu T, et al. Long-term safety, tolerability and efficacy of efgartigimod in patients with generalized myasthenia gravis: interim results of the ADAPT+ study [abstract no. 108]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022.","DOI":"10.1212\/01.wnl.0000903308.81107.e2"},{"key":"1000_CR21","unstructured":"European Medicine Agency. Vyvgart: EU assessment report; 2022. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vyvgart-epar-public-assessment-report_en.pdf. Accessed 7 Feb 2023."},{"key":"1000_CR22","unstructured":"Muppidi S, Pasnoor M, Gelinas D, et al. Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: integrated interim analysis of infection risk and hematological changes [abstract no. 193]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022."},{"issue":"Suppl 1","key":"1000_CR23","first-page":"S91","volume":"64","author":"J Guptill","year":"2021","unstructured":"Guptill J, Sleasman J, Steeland S, et al. Effect of efgartigimod, a neonatal Fc receptor blocker, on humoral vaccine responses in autoimmune patients [abstract]. Muscle Nerve. 2021;64(Suppl 1):S91.","journal-title":"Muscle Nerve"},{"key":"1000_CR24","unstructured":"Qi C, Hughes T, Wang J, et al. Risk benefit analysis of treatment for patients with myasthenia gravis [abstract no. 27]. In: The American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting. 2022."},{"issue":"12","key":"1000_CR25","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1080\/13543784.2021.2010704","volume":"30","author":"R Chen","year":"2021","unstructured":"Chen R, Zhang N, Gao L, et al. Quantitative evaluation of drug efficacy in the treatment of myasthenia gravis. Expert Opin Investig Drugs. 2021;30(12):1231\u201340.","journal-title":"Expert Opin Investig Drugs"},{"issue":"790834","key":"1000_CR26","first-page":"1","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Zhang J, Meng J, et al. Different monoclonal antibodies in myasthenia gravis: a bayesian network meta-analysis. Front Pharmacol. 2021;12(790834):1\u201310.","journal-title":"Front Pharmacol"},{"issue":"18 Suppl","key":"1000_CR27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.98.18_supplement.1531","volume":"98","author":"P-W Lien","year":"2022","unstructured":"Lien P-W, Agboola F, Joshi M, et al. Cost-effectiveness of eculizumab and efgartigimod for the treatment of generalized myasthenia gravis [abstract no. P1\u20131 virtual]. Neurology. 2022;98(18 Suppl):1531.","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1007\/s40263-023-01003-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01000-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01000-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01000-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T05:40:42Z","timestamp":1702186842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01000-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1000"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01000-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"assertion":[{"value":"16 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-023-01003-w","URL":"https:\/\/doi.org\/10.1007\/s40263-023-01003-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Young-A Heo is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}